stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) EV/Sales
As of 6 November 2026, Fortrea Holdings Inc. (FTRE) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.0× (June 2023) to 1.8× (April 2024); the current reading is higher than 62% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | (9.27%) |
| FY2024 | 1.0× | (37.93%) |
| FY2023 | 1.6× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.0× | 8.55% |
| Jun 2026 | 0.9× | 43.52% |
| Mar 2026 | 0.7× | (26.67%) |
| Dec 2025 | 0.9× | 40.88% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 0.9× |
| FTRE Fortrea Holdings Inc. | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.3× |
| BHVN Biohaven Ltd. compare | 2.3× |
| VIR Vir Biotechnology, Inc. compare | 5.3× |
| ZYME Zymeworks Inc. compare | 50.8× |
| IMNM Immunome, Inc. compare | 127× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)